|
3 | 3 | Code |
4 | 4 | res |
5 | 5 | Output |
6 | | - LOW NORMAL HIGH Missing |
7 | | - ————————————————————————————————————————————————————————————————— |
8 | | - Placebo (N=86) |
9 | | - n 0 333 0 3 |
10 | | - LOW 0 84 (25%) 0 0 |
11 | | - NORMAL 0 249 (74.1%) 0 0 |
12 | | - HIGH 0 0 0 0 |
13 | | - Missing 0 0 0 3 (0.9%) |
14 | | - Xanomeline High Dose (N=84) |
15 | | - n 0 327 0 1 |
16 | | - LOW 0 82 (25%) 0 0 |
17 | | - NORMAL 0 245 (74.7%) 0 0 |
18 | | - HIGH 0 0 0 0 |
19 | | - Missing 0 0 0 1 (0.3%) |
20 | | - Xanomeline Low Dose (N=84) |
21 | | - n 0 335 0 1 |
22 | | - LOW 0 84 (25%) 0 0 |
23 | | - NORMAL 0 251 (74.7%) 0 0 |
24 | | - HIGH 0 0 0 0 |
25 | | - Missing 0 0 0 1 (0.3%) |
| 6 | + LOW NORMAL HIGH Missing |
| 7 | + ——————————————————————————————————————————————————————————————————————— |
| 8 | + Placebo (N=84) |
| 9 | + n 37 45 0 2 |
| 10 | + LOW 15 (17.9%) 14 (16.7%) 0 2 (2.4%) |
| 11 | + NORMAL 20 (23.8%) 31 (36.9%) 0 0 |
| 12 | + HIGH 0 0 0 0 |
| 13 | + Missing 2 (2.4%) 0 0 0 |
| 14 | + Xanomeline High Dose (N=82) |
| 15 | + n 30 50 0 2 |
| 16 | + LOW 13 (15.9%) 20 (24.4%) 0 2 (2.4%) |
| 17 | + NORMAL 17 (20.7%) 29 (35.4%) 0 0 |
| 18 | + HIGH 0 0 0 0 |
| 19 | + Missing 0 1 (1.2%) 0 0 |
| 20 | + Xanomeline Low Dose (N=84) |
| 21 | + n 32 51 0 1 |
| 22 | + LOW 10 (11.9%) 21 (25%) 0 1 (1.2%) |
| 23 | + NORMAL 22 (26.2%) 28 (33.3%) 0 0 |
| 24 | + HIGH 0 0 0 0 |
| 25 | + Missing 0 2 (2.4%) 0 0 |
26 | 26 |
|
27 | 27 | # EGT03 variant 2 is produced correctly |
28 | 28 |
|
29 | 29 | Code |
30 | 30 | res |
31 | 31 | Output |
32 | | - NORMAL |
33 | | - ————————————————————————————————————————— |
34 | | - Placebo (N=86) |
35 | | - n 336 |
36 | | - LOW 84 (25%) |
37 | | - NORMAL 249 (74.1%) |
38 | | - HIGH 0 |
39 | | - Missing 3 (0.9%) |
40 | | - Xanomeline High Dose (N=84) |
41 | | - n 328 |
42 | | - LOW 82 (25%) |
43 | | - NORMAL 245 (74.7%) |
44 | | - HIGH 0 |
45 | | - Missing 1 (0.3%) |
46 | | - Xanomeline Low Dose (N=84) |
47 | | - n 336 |
48 | | - LOW 84 (25%) |
49 | | - NORMAL 251 (74.7%) |
50 | | - HIGH 0 |
51 | | - Missing 1 (0.3%) |
| 32 | + LOW NORMAL |
| 33 | + ————————————————————————————————————————————————————— |
| 34 | + Placebo (N=84) |
| 35 | + n 38 46 |
| 36 | + LOW 16 (19%) 15 (17.9%) |
| 37 | + NORMAL 20 (23.8%) 31 (36.9%) |
| 38 | + HIGH 0 0 |
| 39 | + Missing 2 (2.4%) 0 |
| 40 | + Xanomeline High Dose (N=82) |
| 41 | + n 30 52 |
| 42 | + LOW 13 (15.9%) 22 (26.8%) |
| 43 | + NORMAL 17 (20.7%) 29 (35.4%) |
| 44 | + HIGH 0 0 |
| 45 | + Missing 0 1 (1.2%) |
| 46 | + Xanomeline Low Dose (N=84) |
| 47 | + n 32 52 |
| 48 | + LOW 10 (11.9%) 22 (26.2%) |
| 49 | + NORMAL 22 (26.2%) 28 (33.3%) |
| 50 | + HIGH 0 0 |
| 51 | + Missing 0 2 (2.4%) |
52 | 52 |
|
53 | 53 | # EGT03 variant 3 is produced correctly |
54 | 54 |
|
55 | 55 | Code |
56 | 56 | res |
57 | 57 | Output |
58 | | - LOW NORMAL HIGH Missing |
59 | | - ————————————————————————————————————————————————————————————————— |
60 | | - Placebo (N=86) |
61 | | - n 0 333 0 3 |
62 | | - LOW 0 84 (25%) 0 0 |
63 | | - NORMAL 0 249 (74.1%) 0 0 |
64 | | - HIGH 0 0 0 0 |
65 | | - Missing 0 0 0 3 (0.9%) |
66 | | - Xanomeline High Dose (N=84) |
67 | | - n 0 327 0 1 |
68 | | - LOW 0 82 (25%) 0 0 |
69 | | - NORMAL 0 245 (74.7%) 0 0 |
70 | | - HIGH 0 0 0 0 |
71 | | - Missing 0 0 0 1 (0.3%) |
72 | | - Xanomeline Low Dose (N=84) |
73 | | - n 0 335 0 1 |
74 | | - LOW 0 84 (25%) 0 0 |
75 | | - NORMAL 0 251 (74.7%) 0 0 |
76 | | - HIGH 0 0 0 0 |
77 | | - Missing 0 0 0 1 (0.3%) |
| 58 | + LOW NORMAL HIGH Missing |
| 59 | + ——————————————————————————————————————————————————————————————————————— |
| 60 | + Placebo (N=84) |
| 61 | + n 37 45 0 2 |
| 62 | + LOW 15 (17.9%) 14 (16.7%) 0 2 (2.4%) |
| 63 | + NORMAL 20 (23.8%) 31 (36.9%) 0 0 |
| 64 | + HIGH 0 0 0 0 |
| 65 | + Missing 2 (2.4%) 0 0 0 |
| 66 | + Xanomeline High Dose (N=82) |
| 67 | + n 30 50 0 2 |
| 68 | + LOW 13 (15.9%) 20 (24.4%) 0 2 (2.4%) |
| 69 | + NORMAL 17 (20.7%) 29 (35.4%) 0 0 |
| 70 | + HIGH 0 0 0 0 |
| 71 | + Missing 0 1 (1.2%) 0 0 |
| 72 | + Xanomeline Low Dose (N=84) |
| 73 | + n 32 51 0 1 |
| 74 | + LOW 10 (11.9%) 21 (25%) 0 1 (1.2%) |
| 75 | + NORMAL 22 (26.2%) 28 (33.3%) 0 0 |
| 76 | + HIGH 0 0 0 0 |
| 77 | + Missing 0 2 (2.4%) 0 0 |
78 | 78 |
|
79 | 79 | # EGT03 variant 4 is produced correctly |
80 | 80 |
|
81 | 81 | Code |
82 | 82 | res |
83 | 83 | Output |
84 | | - LOW NORMAL HIGH Missing |
85 | | - ————————————————————————————————————————————————————————————————— |
86 | | - Placebo (N=86) |
87 | | - n 0 333 0 3 |
88 | | - LOW 0 84 (25%) 0 0 |
89 | | - NORMAL 0 249 (74.1%) 0 0 |
90 | | - HIGH 0 0 0 0 |
91 | | - Missing 0 0 0 3 (0.9%) |
92 | | - Xanomeline High Dose (N=84) |
93 | | - n 0 327 0 1 |
94 | | - LOW 0 82 (25%) 0 0 |
95 | | - NORMAL 0 245 (74.7%) 0 0 |
96 | | - HIGH 0 0 0 0 |
97 | | - Missing 0 0 0 1 (0.3%) |
98 | | - Xanomeline Low Dose (N=84) |
99 | | - n 0 335 0 1 |
100 | | - LOW 0 84 (25%) 0 0 |
101 | | - NORMAL 0 251 (74.7%) 0 0 |
102 | | - HIGH 0 0 0 0 |
103 | | - Missing 0 0 0 1 (0.3%) |
| 84 | + LOW NORMAL HIGH Missing |
| 85 | + ——————————————————————————————————————————————————————————————————————— |
| 86 | + Placebo (N=84) |
| 87 | + n 37 45 0 2 |
| 88 | + LOW 15 (17.9%) 14 (16.7%) 0 2 (2.4%) |
| 89 | + NORMAL 20 (23.8%) 31 (36.9%) 0 0 |
| 90 | + HIGH 0 0 0 0 |
| 91 | + Missing 2 (2.4%) 0 0 0 |
| 92 | + Xanomeline High Dose (N=82) |
| 93 | + n 30 50 0 2 |
| 94 | + LOW 13 (15.9%) 20 (24.4%) 0 2 (2.4%) |
| 95 | + NORMAL 17 (20.7%) 29 (35.4%) 0 0 |
| 96 | + HIGH 0 0 0 0 |
| 97 | + Missing 0 1 (1.2%) 0 0 |
| 98 | + Xanomeline Low Dose (N=84) |
| 99 | + n 32 51 0 1 |
| 100 | + LOW 10 (11.9%) 21 (25%) 0 1 (1.2%) |
| 101 | + NORMAL 22 (26.2%) 28 (33.3%) 0 0 |
| 102 | + HIGH 0 0 0 0 |
| 103 | + Missing 0 2 (2.4%) 0 0 |
104 | 104 |
|
0 commit comments